GUT:胰腺癌切除术的国际间差异研究!

2017-11-22 MedSci MedSci原创

对于能够切除的胰腺癌(PaC)患者进行手术切除可以使这部分患者得到治愈,并能够显着延长部分患者的生存期。近期,一项发表在杂志GUT上的大规模国际研究旨在调查欧洲和美国PaC切除的差异及其使用的决定因素。此项研究分析了2003-2016年期间,欧洲六个人口癌症登记处以及美国监测、流行病学和最终结果计划数据库的数据。计算了总体和I-II 期PaCs患者的年龄标准化切除率。切除与人口统计学和临床参数之间

对于能够切除的胰腺癌(PaC)患者进行手术切除可以使这部分患者得到治愈,并能够显着延长部分患者的生存期。


近期,一项发表在杂志GUT上的大规模国际研究旨在调查欧洲和美国PaC切除的差异及其使用的决定因素。

此项研究分析了2003-2016年期间,欧洲六个人口癌症登记处以及美国监测、流行病学和最终结果计划数据库的数据。计算了总体和I-II 期PaCs患者的年龄标准化切除率。切除与人口统计学和临床参数之间的关联使用多变量逻辑回归模型进行评估。

最终,此项研究共分析了153698条记录。在2012-2014年的人口基础登记中,总体切除率从Estonia的13.2%到Slovenia的21.2%;I-II期的切除率从Norway的34.8%到Denmark的68.7% 。

在2003-2014年期间,切除率只在美国、荷兰和丹麦地区上升。在进展期的肿瘤阶段(Ⅲ,Ⅳ期 vs Ⅰ-Ⅱ期肿瘤的OR值:各国0.05-0.18和0.01-0.06)以及年龄增加(70-79岁和≥80岁 vs. <60岁的ORs:各国为0.37-0.63和0.03-0.16)的人群中切除率更低。

很少接受切除的晚期肿瘤(III-IV期:63.8%-81.2%)和年龄较大(≥70岁:52.6%-59.5%)的患者占绝大多数的确诊病例。患者的疾病状况、肿瘤的位置和大小也与是否切除有关。

此项研究结果表明:在欧洲和美国,PaC的切除率仍然很低,并且,PaC的切除情况在国际上有很大的差异。

原始出处:
Huang L, Jansen L, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. 2017 Nov 20. pii: gutjnl-2017-314828. doi: 10.1136/gutjnl-2017-314828. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1876968, encodeId=164518e69680e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Mar 13 06:34:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263512, encodeId=659d26351281, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/04/7e2c04a7e58b6065a1392efd799c6a6b.jpg, createdBy=de482077642, createdName=王晓霞, createdTime=Thu Nov 23 06:51:30 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263419, encodeId=b5a72634196b, content=谢谢分享学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Nov 22 21:18:27 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263406, encodeId=f5a326340607, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Nov 22 19:55:05 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1876968, encodeId=164518e69680e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Mar 13 06:34:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263512, encodeId=659d26351281, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/04/7e2c04a7e58b6065a1392efd799c6a6b.jpg, createdBy=de482077642, createdName=王晓霞, createdTime=Thu Nov 23 06:51:30 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263419, encodeId=b5a72634196b, content=谢谢分享学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Nov 22 21:18:27 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263406, encodeId=f5a326340607, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Nov 22 19:55:05 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2017-11-23 王晓霞

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1876968, encodeId=164518e69680e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Mar 13 06:34:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263512, encodeId=659d26351281, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/04/7e2c04a7e58b6065a1392efd799c6a6b.jpg, createdBy=de482077642, createdName=王晓霞, createdTime=Thu Nov 23 06:51:30 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263419, encodeId=b5a72634196b, content=谢谢分享学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Nov 22 21:18:27 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263406, encodeId=f5a326340607, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Nov 22 19:55:05 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2017-11-22 戒馋,懒,贪

    谢谢分享学习了.

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1876968, encodeId=164518e69680e, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Tue Mar 13 06:34:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263512, encodeId=659d26351281, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/04/7e2c04a7e58b6065a1392efd799c6a6b.jpg, createdBy=de482077642, createdName=王晓霞, createdTime=Thu Nov 23 06:51:30 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263419, encodeId=b5a72634196b, content=谢谢分享学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Nov 22 21:18:27 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263406, encodeId=f5a326340607, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Nov 22 19:55:05 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2017-11-22 thlabcde

    好资料学习了!

    0

相关资讯

Diabetes Care:基于肠促胰岛素治疗和胰腺癌的短期风险!

由此可见,采用肠促胰岛素治疗与胰腺癌风险增加有关。这种增加的原因可能是引发或加重糖尿病的隐匿性胰腺癌的结果,评估肠促胰岛素药物长期使用相关的胰腺癌风险需要进行进一步研究。

ANN ONCOL:非转移性胰腺癌化疗后如何选择需进行手术切除的患者

交界性(BL)或局部晚期(LA)胰腺癌患者通常需要先进行化疗后选择合适的患者进行手术切除。ANN ONCOL近期发表了一篇文章,研究化疗后可以进行切除的患者的选择标准。

JAMA:胰腺癌患者存活时间竟由这四种基因决定!

https://www.ncbi.nlm.nih.gov/pubmed/?term=Association+of+Alterations+in+Main+Driver+Genes+With+Outcomes+of+Patients+With+Resected+Pancreatic+Ductal+Adenocarcinoma

张艳桥教授:枯树逢春——胰腺癌免疫治疗有待突破

本次中国抗癌协会胰腺癌专业委员会年会特邀国内胰腺肿瘤领域的顶尖专家谈“胰”论道,是一次内容翔实丰富、形式新颖多样的专科学术会议。会后,哈尔滨医科大学附属肿瘤医院的张艳桥教授就胰腺癌的免疫治疗进展、青年胰腺癌专家的教育和培养等问题接受了我们的采访。

Sci Rep:循环miRNA-21-5p或是早期胰腺癌诊断的生物标志物

世界范围内胰腺癌(PC)是一种高致命性疾病,其早期阶段常常被误诊。探索新型非侵入性生物标志物必定会使PC患者受益。最近,体液中的循环miRNAs正在成为PC诊断的非侵入性生物标志物。在本研究中,我们首先对21个已发表的miRome谱分析研究进行了全面的稳健的秩聚合(RRA)分析。我们统计确定并临床验证PC患者中的miRNA表达模式。这些miRNAs包括四个上调miRNAs(hsa-miR-21-5

[胰腺癌年会]虞先濬教授畅谈胰腺癌治愈之路

胰腺癌“癌中之王”的称号可能会让很多人闻风丧胆,临床肿瘤专家对胰腺癌的治疗可谓是绞尽脑汁、鞠躬尽瘁。胰腺癌的治疗由原来的单一手术治疗到现在的药物治疗等的出现,给患者带来了更多的选择。2017年10月27日-29日,中国抗癌协会胰腺癌专业委员会年会在天津召开。